Pfizer recently divested a portion of its investment in the consumer-healthcare company Haleon, cashing in approximately £2.75 billion ($3.50 billion). This strategic sale reduced Pfizer’s ownership in Haleon from 32% to 22.6%, involving the sale of 790.6 million Haleon shares at a price of 308 pence each. This pricing marked a 7% discount to Haleon’s closing price of 332.30 pence on the preceding Friday, totaling a sale value of £2.43 billion.

Initially, Haleon had disclosed plans for Pfizer to sell 630 million shares to decrease its stake to 24%. However, the final sale exceeded these expectations, further reducing Pfizer’s holding in the company.

In a related transaction, Haleon confirmed the off-market repurchase of 102.3 million of its shares from Pfizer, executed at the same price as the broader sale, amounting to approximately £315 million. This move reflects Haleon’s strategic efforts to manage its share capital post-Pfizer’s divestiture.

Join the discussion: Connect with other investors on your favorite stocks or explore the top-talked-about stocks on our Breakout Boards.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.